RU2721555C2 - Композиции, содержащие 15-hepe, и способы лечения или предотвращения фиброза с применением указанных композиций - Google Patents

Композиции, содержащие 15-hepe, и способы лечения или предотвращения фиброза с применением указанных композиций Download PDF

Info

Publication number: RU2721555C2
Authority: RU; Russia
Prior art keywords: approximately; hepe; agent; fibrosis; subject
Prior art date: 2014-12-02

Application number

RU2017122758A

Other languages

English (en)

Russian (ru)

Other versions

RU2017122758A (ru

RU2017122758A3 (2

Inventor

Джонатан РОУ

Кевин ДАФФИ

Джон КЛАЙМАКС

Original Assignee

Эфиммьюн Лимитед

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-02

Filing date

2015-12-02

Publication date

2020-05-20

2015-12-02 Application filed by Эфиммьюн Лимитед filed Critical Эфиммьюн Лимитед

2019-01-09 Publication of RU2017122758A publication Critical patent/RU2017122758A/ru

2019-06-13 Publication of RU2017122758A3 publication Critical patent/RU2017122758A3/ru

2020-05-20 Application granted granted Critical

2020-05-20 Publication of RU2721555C2 publication Critical patent/RU2721555C2/ru

Links

239000000203 mixture Substances 0.000 title claims abstract description 72
238000000034 method Methods 0.000 title claims abstract description 54
206010016654 Fibrosis Diseases 0.000 title claims description 53
230000004761 fibrosis Effects 0.000 title claims description 53
230000000694 effects Effects 0.000 claims abstract description 12
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims abstract description 10
208000036971 interstitial lung disease 2 Diseases 0.000 claims abstract description 10
WLKCSMCLEKGITB-XWJJKCKWSA-N 15-HEPE Chemical compound CC\C=C/CC(O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-XWJJKCKWSA-N 0.000 claims abstract 16
239000003795 chemical substances by application Substances 0.000 claims description 60
RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 45
239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 23
229960005187 telmisartan Drugs 0.000 claims description 22
238000011282 treatment Methods 0.000 claims description 20
150000001875 compounds Chemical class 0.000 claims description 11
230000008569 process Effects 0.000 claims description 11
239000002253 acid Substances 0.000 claims description 9
239000003112 inhibitor Substances 0.000 claims description 9
241000711549 Hepacivirus C Species 0.000 claims description 8
239000003443 antiviral agent Substances 0.000 claims description 8
210000002966 serum Anatomy 0.000 claims description 8
230000002265 prevention Effects 0.000 claims description 7
241000700721 Hepatitis B virus Species 0.000 claims description 6
210000004027 cell Anatomy 0.000 claims description 6
206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 6
150000003839 salts Chemical group 0.000 claims description 6
125000005907 alkyl ester group Chemical group 0.000 claims description 4
102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims description 3
102000011690 Adiponectin Human genes 0.000 claims description 3
108010076365 Adiponectin Proteins 0.000 claims description 3
102000008873 Angiotensin II receptor Human genes 0.000 claims description 3
108050000824 Angiotensin II receptor Proteins 0.000 claims description 3
206010003827 Autoimmune hepatitis Diseases 0.000 claims description 3
239000005485 Azilsartan Substances 0.000 claims description 3
208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 3
208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 3
101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 3
239000002080 C09CA02 - Eprosartan Substances 0.000 claims description 3
239000004072 C09CA03 - Valsartan Substances 0.000 claims description 3
229940126692 CXCR3 antagonist Drugs 0.000 claims description 3
206010008609 Cholangitis sclerosing Diseases 0.000 claims description 3
201000003883 Cystic fibrosis Diseases 0.000 claims description 3
206010064212 Eosinophilic oesophagitis Diseases 0.000 claims description 3
108010072051 Glatiramer Acetate Proteins 0.000 claims description 3
101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims description 3
208000012654 Primary biliary cholangitis Diseases 0.000 claims description 3
102000009266 Y-Box-Binding Protein 1 Human genes 0.000 claims description 3
108010048626 Y-Box-Binding Protein 1 Proteins 0.000 claims description 3
229940121359 adenosine receptor antagonist Drugs 0.000 claims description 3
239000000556 agonist Substances 0.000 claims description 3
239000005557 antagonist Substances 0.000 claims description 3
230000002075 anti-alcohol Effects 0.000 claims description 3
230000003367 anti-collagen effect Effects 0.000 claims description 3
KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 claims description 3
229960002731 azilsartan Drugs 0.000 claims description 3
239000003067 chemokine receptor CCR5 antagonist Substances 0.000 claims description 3
239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 claims description 3
229940038717 copaxone Drugs 0.000 claims description 3
239000003431 cross linking reagent Substances 0.000 claims description 3
229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 claims description 3
201000000708 eosinophilic esophagitis Diseases 0.000 claims description 3
OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims description 3
229960004563 eprosartan Drugs 0.000 claims description 3
239000000411 inducer Substances 0.000 claims description 3
229960005108 mepolizumab Drugs 0.000 claims description 3
239000002679 microRNA Substances 0.000 claims description 3
229950007699 mogamulizumab Drugs 0.000 claims description 3
206010028537 myelofibrosis Diseases 0.000 claims description 3
210000000651 myofibroblast Anatomy 0.000 claims description 3
230000001722 neurochemical effect Effects 0.000 claims description 3
201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 3
208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
239000000296 purinergic P1 receptor antagonist Substances 0.000 claims description 3
239000003087 receptor blocking agent Substances 0.000 claims description 3
102000005962 receptors Human genes 0.000 claims description 3
108020003175 receptors Proteins 0.000 claims description 3
230000007115 recruitment Effects 0.000 claims description 3
201000002793 renal fibrosis Diseases 0.000 claims description 3
208000010157 sclerosing cholangitis Diseases 0.000 claims description 3
229950009513 simtuzumab Drugs 0.000 claims description 3
210000000130 stem cell Anatomy 0.000 claims description 3
229960004556 tenofovir Drugs 0.000 claims description 3
VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 3
125000005457 triglyceride group Chemical group 0.000 claims description 3
229960004699 valsartan Drugs 0.000 claims description 3
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 3
206010019728 Hepatitis alcoholic Diseases 0.000 claims description 2
239000005480 Olmesartan Substances 0.000 claims description 2
208000002353 alcoholic hepatitis Diseases 0.000 claims description 2
VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims description 2
229960005117 olmesartan Drugs 0.000 claims description 2
108091070501 miRNA Proteins 0.000 claims 2
102100037853 C-C chemokine receptor type 4 Human genes 0.000 claims 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 1
230000002300 anti-fibrosis Effects 0.000 claims 1
210000002744 extracellular matrix Anatomy 0.000 claims 1
239000003814 drug Substances 0.000 abstract description 7
238000004519 manufacturing process Methods 0.000 abstract description 5
239000000126 substance Substances 0.000 abstract description 4
102000004887 Transforming Growth Factor beta Human genes 0.000 abstract description 3
108090001012 Transforming Growth Factor beta Proteins 0.000 abstract description 3
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract description 3
102000007469 Actins Human genes 0.000 abstract 1
108010085238 Actins Proteins 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
210000003205 muscle Anatomy 0.000 abstract 1
WGDOCGARYFJEEV-UHFFFAOYSA-N 2-hydroxyicosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=C(O)C(O)=O WGDOCGARYFJEEV-UHFFFAOYSA-N 0.000 description 114
241000699670 Mus sp. Species 0.000 description 34
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
235000019197 fats Nutrition 0.000 description 21
235000005911 diet Nutrition 0.000 description 20
230000037213 diet Effects 0.000 description 20
239000008194 pharmaceutical composition Substances 0.000 description 18
201000010099 disease Diseases 0.000 description 16
208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 16
208000035475 disorder Diseases 0.000 description 15
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 13
239000002552 dosage form Substances 0.000 description 13
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 13
229960005135 eicosapentaenoic acid Drugs 0.000 description 12
235000020673 eicosapentaenoic acid Nutrition 0.000 description 12
210000000056 organ Anatomy 0.000 description 9
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
235000013305 food Nutrition 0.000 description 7
208000024891 symptom Diseases 0.000 description 7
-1 15-HEPE methyl ester Chemical class 0.000 description 6
239000013543 active substance Substances 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
210000004072 lung Anatomy 0.000 description 6
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
108010082126 Alanine transaminase Proteins 0.000 description 5
102000008186 Collagen Human genes 0.000 description 5
108010035532 Collagen Proteins 0.000 description 5
108010007622 LDL Lipoproteins Proteins 0.000 description 5
102000007330 LDL Lipoproteins Human genes 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
108010062497 VLDL Lipoproteins Proteins 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
208000019425 cirrhosis of liver Diseases 0.000 description 5
229920001436 collagen Polymers 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
230000000840 anti-viral effect Effects 0.000 description 4
239000003963 antioxidant agent Substances 0.000 description 4
235000006708 antioxidants Nutrition 0.000 description 4
239000002775 capsule Substances 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
210000005228 liver tissue Anatomy 0.000 description 4
239000000902 placebo Substances 0.000 description 4
229940068196 placebo Drugs 0.000 description 4
239000003826 tablet Substances 0.000 description 4
229940124597 therapeutic agent Drugs 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
150000003626 triacylglycerols Chemical class 0.000 description 4
OWFVSJHRFRIEAK-UHFFFAOYSA-N 15-hydroxyicosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCC(O)CCCC=CC=CC=CC=CC=CC(O)=O OWFVSJHRFRIEAK-UHFFFAOYSA-N 0.000 description 3
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
238000011161 development Methods 0.000 description 3
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
235000004626 essential fatty acids Nutrition 0.000 description 3
210000002216 heart Anatomy 0.000 description 3
238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
229960002591 hydroxyproline Drugs 0.000 description 3
230000003993 interaction Effects 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
239000007937 lozenge Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
210000001370 mediastinum Anatomy 0.000 description 3
235000020660 omega-3 fatty acid Nutrition 0.000 description 3
229940012843 omega-3 fatty acid Drugs 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
230000001850 reproductive effect Effects 0.000 description 3
210000000574 retroperitoneal space Anatomy 0.000 description 3
238000013424 sirius red staining Methods 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 3
231100000402 unacceptable toxicity Toxicity 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
239000002083 C09CA01 - Losartan Substances 0.000 description 2
239000002947 C09CA04 - Irbesartan Substances 0.000 description 2
102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 2
ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
108700011259 MicroRNAs Proteins 0.000 description 2
206010050207 Skin fibrosis Diseases 0.000 description 2
244000269722 Thea sinensis Species 0.000 description 2
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
235000017471 coenzyme Q10 Nutrition 0.000 description 2
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000008021 deposition Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
125000004494 ethyl ester group Chemical group 0.000 description 2
210000001508 eye Anatomy 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
235000009569 green tea Nutrition 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
229960002198 irbesartan Drugs 0.000 description 2
YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
229960004773 losartan Drugs 0.000 description 2
KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
239000006014 omega-3 oil Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000003313 weakening effect Effects 0.000 description 2
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
125000006724 (C1-C5) alkyl ester group Chemical group 0.000 description 1
KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
WLKCSMCLEKGITB-DBVSHIMFSA-N 15(S)-HEPE Chemical compound CC\C=C/C[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-DBVSHIMFSA-N 0.000 description 1
GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
102000009515 Arachidonate 15-Lipoxygenase Human genes 0.000 description 1
108010048907 Arachidonate 15-lipoxygenase Proteins 0.000 description 1
241000725101 Clea Species 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 1
WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
238000013232 NAFLD rodent model Methods 0.000 description 1
SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
244000046052 Phaseolus vulgaris Species 0.000 description 1
235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
244000294611 Punica granatum Species 0.000 description 1
235000014360 Punica granatum Nutrition 0.000 description 1
241000700159 Rattus Species 0.000 description 1
QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
241000533293 Sesbania emerus Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
102100021947 Survival motor neuron protein Human genes 0.000 description 1
LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
235000009754 Vitis X bourquina Nutrition 0.000 description 1
235000012333 Vitis X labruscana Nutrition 0.000 description 1
240000006365 Vitis vinifera Species 0.000 description 1
235000014787 Vitis vinifera Nutrition 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
235000020661 alpha-linolenic acid Nutrition 0.000 description 1
230000000511 anti-eosinophil effect Effects 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000010385 ascorbyl palmitate Nutrition 0.000 description 1
239000003212 astringent agent Substances 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
238000009534 blood test Methods 0.000 description 1
239000007894 caplet Substances 0.000 description 1
ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
150000001765 catechin Chemical class 0.000 description 1
235000005487 catechin Nutrition 0.000 description 1
230000006041 cell recruitment Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
229940110767 coenzyme Q10 Drugs 0.000 description 1
229920002770 condensed tannin Polymers 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
235000020669 docosahexaenoic acid Nutrition 0.000 description 1
KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
239000000284 extract Substances 0.000 description 1
KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
229940114124 ferulic acid Drugs 0.000 description 1
235000001785 ferulic acid Nutrition 0.000 description 1
KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
229940045109 genistein Drugs 0.000 description 1
235000006539 genistein Nutrition 0.000 description 1
TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
229960004135 idebenone Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical group 0.000 description 1
229960004488 linolenic acid Drugs 0.000 description 1
239000008263 liquid aerosol Substances 0.000 description 1
229910003002 lithium salt Inorganic materials 0.000 description 1
159000000002 lithium salts Chemical class 0.000 description 1
235000012661 lycopene Nutrition 0.000 description 1
229960004999 lycopene Drugs 0.000 description 1
OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
239000001751 lycopene Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
229960003966 nicotinamide Drugs 0.000 description 1
235000005152 nicotinamide Nutrition 0.000 description 1
239000011570 nicotinamide Substances 0.000 description 1
231100001083 no cytotoxicity Toxicity 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
235000018192 pine bark supplement Nutrition 0.000 description 1
150000008442 polyphenolic compounds Chemical class 0.000 description 1
235000013824 polyphenols Nutrition 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
229940106796 pycnogenol Drugs 0.000 description 1
238000011002 quantification Methods 0.000 description 1
NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
238000011160 research Methods 0.000 description 1
230000008458 response to injury Effects 0.000 description 1
235000021283 resveratrol Nutrition 0.000 description 1
229940016667 resveratrol Drugs 0.000 description 1
238000012216 screening Methods 0.000 description 1
SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
229960004245 silymarin Drugs 0.000 description 1
235000017700 silymarin Nutrition 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 1
238000003860 storage Methods 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
229940035936 ubiquinone Drugs 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pulmonology (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

RU2017122758A 2014-12-02 2015-12-02 Композиции, содержащие 15-hepe, и способы лечения или предотвращения фиброза с применением указанных композиций RU2721555C2 (ru)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462086535P	2014-12-02	2014-12-02
US62/086,535		2014-12-02
PCT/US2015/063488 WO2016090030A1 (en)	2014-12-02	2015-12-02	Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2020115523A Division RU2020115523A (ru)	2014-12-02	2015-12-02	Композиции, содержащие 15-hepe, и способы лечения или предотвращения фиброза с применением указанных композиций

Publications (3)

Publication Number	Publication Date
RU2017122758A RU2017122758A (ru)	2019-01-09
RU2017122758A3 RU2017122758A3 (2)	2019-06-13
RU2721555C2 true RU2721555C2 (ru)	2020-05-20

Family

ID=56092410

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
RU2017122758A RU2721555C2 (ru)	2014-12-02	2015-12-02	Композиции, содержащие 15-hepe, и способы лечения или предотвращения фиброза с применением указанных композиций
RU2020115523A RU2020115523A (ru)	2014-12-02	2015-12-02	Композиции, содержащие 15-hepe, и способы лечения или предотвращения фиброза с применением указанных композиций

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
RU2020115523A RU2020115523A (ru)	2014-12-02	2015-12-02	Композиции, содержащие 15-hepe, и способы лечения или предотвращения фиброза с применением указанных композиций

Country Status (17)

Country	Link
US (1)	US10363235B2 (2)
EP (2)	EP3226873B1 (2)
JP (2)	JP6986445B2 (2)
KR (1)	KR20170102879A (2)
CN (2)	CN107206008A (2)
AU (2)	AU2015358512B2 (2)
BR (1)	BR112017011685A2 (2)
CA (1)	CA2968980A1 (2)
ES (1)	ES2900593T3 (2)
IL (2)	IL252431B (2)
MA (1)	MA41120A (2)
MX (2)	MX382116B (2)
PH (1)	PH12017501022B1 (2)
RU (2)	RU2721555C2 (2)
SG (2)	SG11201704495VA (2)
WO (1)	WO2016090030A1 (2)
ZA (2)	ZA201704463B (2)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201301626D0 (en) *	2013-01-30	2013-03-13	Dignity Sciences Ltd	Composition comprising 15-OHEPA and methods of using the same
JP2016538288A (ja)	2013-11-15	2016-12-08	ディグニティサイエンシスリミテッド	多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
EP3091959A4 (en) *	2014-01-10	2017-09-20	Dignity Sciences Limited	Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
US20180008567A1 (en) *	2015-01-16	2018-01-11	Afimmune Limited	Compositions comprising 15-hepe and methods of using the same
MA47141A (fr)	2015-05-13	2019-11-06	Ds Biopharma Ltd	Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
CA3129008A1 (en) *	2015-12-18	2017-06-22	Afimmune Limited	Compositions comprising 15-hepe and methods of using the same
US20210315851A1 (en)	2020-04-03	2021-10-14	Afimmune Limited	Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999045916A2 (en) *	1998-03-10	1999-09-16	Beth Israel Deaconess Medical Center Inc.	Novel methods for treating disorders in which docosahexaenoic acid (dha) levels are affected
WO2001049282A2 (en) *	2000-01-06	2001-07-12	Martek Biosciences Corporation	Therapeutic preparations of highly unsaturated fatty acids
US20120264824A1 (en) *	2011-04-15	2012-10-18	Mochida Pharmaceutical Co., Ltd.	Compositions and methods for treating non-alcoholic steatohepatitis
WO2014118097A1 (en) *	2013-01-30	2014-08-07	Dignity Sciences Limited	Compositions comprising 15-ohepa and methods of using the same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2000191525A (ja)	1998-12-25	2000-07-11	Nof Corp	皮膚外用剤組成物
EP1762557B1 (en)	2000-02-16	2011-04-06	The Brigham And Women's Hospital, Inc.	Aspirin-triggered lipid mediators
JP2005179211A (ja)	2003-12-17	2005-07-07	Idemitsu Kosan Co Ltd	皮膚外用剤組成物
EP1711173A2 (en)	2003-12-31	2006-10-18	Igennus Limited	Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
WO2005102309A2 (en)	2004-04-26	2005-11-03	Ltb4 Sweden Ab	In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
EP3285072B1 (en) *	2006-08-08	2020-04-15	Metabolon, Inc.	Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
US8042070B2 (en) *	2007-10-23	2011-10-18	International Business Machines Corporation	Methods and system for analysis and management of parametric yield
GB0802116D0 (en) *	2008-02-05	2008-03-12	Natural Enviromental Res Counc	Treatment
PE20100156A1 (es) *	2008-06-03	2010-02-23	Boehringer Ingelheim Int	Tratamiento de nafld
US20110105510A1 (en)	2008-06-17	2011-05-05	Hiroshi Ishikawa	Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
WO2010120880A1 (en) *	2009-04-14	2010-10-21	Vertex Pharmaceuticals Incorporated	Treatment of liver diseases with a caspase inhibitor
GB0907413D0 (en)	2009-04-29	2009-06-10	Equateq Ltd	Novel methods
US10154977B2 (en) *	2011-03-25	2018-12-18	The Brigham And Women's Hospital, Inc.	Anti-inflammatory particles
MX360979B (es) *	2011-09-16	2018-11-22	Galectin Therapeutics Inc	Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico.
RU2014119948A (ru)	2011-10-19	2015-11-27	Дигнити Сайенсиз Лимитед	ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ DGLA И/ИЛИ 15-HETrE, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US8293790B2 (en)	2011-10-19	2012-10-23	Dignity Sciences Limited	Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
JP2015500639A (ja)	2011-11-29	2015-01-08	ディグニティサイエンシスリミテッド	２０−炭素脂肪酸を含む組成物ならびにその製造方法および使用方法
CN104302305A (zh) *	2011-12-16	2015-01-21	塔瑞克斯制药有限公司	用于治疗纤维化的血管紧张素
US20120264705A1 (en)	2012-01-26	2012-10-18	Dignity Sciences Limited	Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en)	2012-02-23	2013-10-10	Dignity Sciences Limited	Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
DK2858496T3 (da)	2012-05-10	2023-07-24	Solutex Na Llc	Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
TWI742541B (zh) *	2013-03-15	2021-10-11	英商邊緣生物科技有限公司	用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
CA3129008A1 (en)	2015-12-18	2017-06-22	Afimmune Limited	Compositions comprising 15-hepe and methods of using the same

2015
- 2015-12-01 MA MA041120A patent/MA41120A/fr unknown
- 2015-12-02 WO PCT/US2015/063488 patent/WO2016090030A1/en not_active Ceased
- 2015-12-02 CN CN201580074543.0A patent/CN107206008A/zh active Pending
- 2015-12-02 JP JP2017527848A patent/JP6986445B2/ja not_active Expired - Fee Related
- 2015-12-02 SG SG11201704495VA patent/SG11201704495VA/en unknown
- 2015-12-02 RU RU2017122758A patent/RU2721555C2/ru active
- 2015-12-02 SG SG10202010594WA patent/SG10202010594WA/en unknown
- 2015-12-02 EP EP15865150.5A patent/EP3226873B1/en active Active
- 2015-12-02 BR BR112017011685-5A patent/BR112017011685A2/pt not_active Application Discontinuation
- 2015-12-02 CA CA2968980A patent/CA2968980A1/en not_active Abandoned
- 2015-12-02 RU RU2020115523A patent/RU2020115523A/ru unknown
- 2015-12-02 KR KR1020177018195A patent/KR20170102879A/ko not_active Withdrawn
- 2015-12-02 CN CN202011279675.6A patent/CN112245419A/zh active Pending
- 2015-12-02 MX MX2017007000A patent/MX382116B/es unknown
- 2015-12-02 ES ES15865150T patent/ES2900593T3/es active Active
- 2015-12-02 AU AU2015358512A patent/AU2015358512B2/en not_active Ceased
- 2015-12-02 EP EP21200516.9A patent/EP3988101A1/en not_active Withdrawn
2016
- 2016-03-07 US US15/062,636 patent/US10363235B2/en active Active
2017
- 2017-05-22 IL IL252431A patent/IL252431B/en unknown
- 2017-05-29 MX MX2021005080A patent/MX2021005080A/es unknown
- 2017-06-01 PH PH12017501022A patent/PH12017501022B1/en unknown
- 2017-06-30 ZA ZA2017/04463A patent/ZA201704463B/en unknown
2018
- 2018-06-29 ZA ZA2018/04380A patent/ZA201804380B/en unknown
2021
- 2021-05-18 AU AU2021203189A patent/AU2021203189A1/en not_active Abandoned
- 2021-11-10 IL IL287983A patent/IL287983A/en unknown
- 2021-11-29 JP JP2021192836A patent/JP2022031813A/ja active Pending

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999045916A2 (en) *	1998-03-10	1999-09-16	Beth Israel Deaconess Medical Center Inc.	Novel methods for treating disorders in which docosahexaenoic acid (dha) levels are affected
WO2001049282A2 (en) *	2000-01-06	2001-07-12	Martek Biosciences Corporation	Therapeutic preparations of highly unsaturated fatty acids
US20120264824A1 (en) *	2011-04-15	2012-10-18	Mochida Pharmaceutical Co., Ltd.	Compositions and methods for treating non-alcoholic steatohepatitis
WO2014118097A1 (en) *	2013-01-30	2014-08-07	Dignity Sciences Limited	Compositions comprising 15-ohepa and methods of using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAJIKAWA S et al. Eicosapantaenoie Acid Attenuates Progression in Rats Fed Methionin- and Choline-Deficient Diet//Digestive Diseases and Sciences, 2010, 56(4), 1065-1074. *

Also Published As

Publication number	Publication date
IL287983A (en)	2022-01-01
MX382116B (es)	2025-03-13
CN107206008A (zh)	2017-09-26
ZA201704463B (en)	2018-11-28
ES2900593T3 (es)	2022-03-17
JP6986445B2 (ja)	2021-12-22
US20160184252A1 (en)	2016-06-30
MX2021005080A (es)	2021-06-15
IL252431B (en)	2021-12-01
US10363235B2 (en)	2019-07-30
MX2017007000A (es)	2017-12-07
RU2017122758A (ru)	2019-01-09
SG10202010594WA (en)	2020-12-30
IL252431A0 (en)	2017-07-31
MA41120A (fr)	2017-10-10
EP3226873A1 (en)	2017-10-11
CA2968980A1 (en)	2016-06-09
PH12017501022B1 (en)	2022-02-16
RU2020115523A (ru)	2021-01-27
RU2017122758A3 (2)	2019-06-13
EP3226873B1 (en)	2021-10-27
SG11201704495VA (en)	2017-06-29
PH12017501022A1 (en)	2017-11-27
JP2022031813A (ja)	2022-02-22
HK1245101A1 (zh)	2018-08-24
AU2015358512B2 (en)	2021-02-18
AU2021203189A1 (en)	2021-06-10
EP3226873A4 (en)	2018-08-08
AU2015358512A1 (en)	2017-07-20
KR20170102879A (ko)	2017-09-12
ZA201804380B (en)	2021-03-31
WO2016090030A1 (en)	2016-06-09
BR112017011685A2 (pt)	2018-01-02
JP2017536380A (ja)	2017-12-07
EP3988101A1 (en)	2022-04-27
CN112245419A (zh)	2021-01-22

Publication	Publication Date	Title
RU2721555C2 (ru)	2020-05-20	Композиции, содержащие 15-hepe, и способы лечения или предотвращения фиброза с применением указанных композиций
KR102434817B1 (ko)	2022-08-19	15-hepe를 포함하는 조성물 및 그의 사용 방법
JP7053478B2 (ja)	2022-04-12	Ｆｘｒアゴニストを使用するための方法
JP2020516627A (ja)	2020-06-11	肝疾患を処置する方法
IL266530B2 (en)	2024-09-01	Aramchol for use in fibrosis treatment
Cardoso et al.	2020	New drugs for non‐alcoholic steatohepatitis
JP7229285B2 (ja)	2023-02-27	１５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法
JP6878596B2 (ja)	2021-05-26	Ｆｘｒアゴニストの組合せ
KR20210110407A (ko)	2021-09-07	Fxr 작용제의 신규 요법
CN107405324A (zh)	2017-11-28	包含15‑hepe的组合物和其使用方法
KR20220038339A (ko)	2022-03-28	Sglt 억제제, 예를 들어 sglt 1/2 억제제를 포함하는 치료
HK1245101B (en)	2022-02-18	Compositions comprising 15-hepe and its use for treating or preventing idiopathic pulomonary fibrosis
Wang et al.	2025	A GLP-1 receptor agonist semaglutide attenuates cardiac microvascular injury in HFD/STZ-induced diabetic mice
KR20210015849A (ko)	2021-02-10	트로피펙소르 및 세니크리비록을 포함하는 조합물
JP2022533603A (ja)	2022-07-25	１５－ＨＥＰＥおよび／または１５－ＨＥＴｒＥを含む組成物、ならびに心血管代謝性疾患、メタボリックシンドローム、および／または関連疾患を治療または予防する方法
WO2025247183A1 (zh)	2025-12-04	桑提取物在制备治疗和/或预防糖尿病血管并发症的药物中的用途
Berthold et al.	2006	Th-P16: 328 Policosanol does not lower cholesterol in caucasian patients with hypercholesterolemia or combined hyperlipidemia—An RCT with usual and high doses
HK40032085A (en)	2021-03-19	Method of using cyclodextrin
Kesavadev et al.	2013	Improvement of glycemic control with addition of insulin detemir to existing antidiabetic therapy: a sub-group analysis of A1chieve observational study